Skip to main content

Table 3 Antigen specific T cell responses

From: Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

Patient Number Peak 5T4 polyclonal precursor frequencies ORR (month)
  Time point (week) Peptides alone Time Point (week) Protein + Peptides  
1 - < 1/200,000 - < 1/200,000 PD
2 - < 1/200,000 3 1/19,231 PD
3 - < 1/200,000 - < 1/200,000 PD
5 55 1/12,048 55 1/1,701 Surgical CR(50+)
6 26 1/21,277 26 1/21,277 SD (13)
7 29 1/2,113 29 1/2,113 SD (9)
8 - < 1/200,000 - < 1/200,000 PD
9 105 1/993 105 1/993 Surgical CR(54+)
10 - < 1/200,000 - < 1/200,000 PD
11 - < 1/200,000 9 1/12,500 SD (2)
12 - < 1/200,000 - < 1/200,000 PD
13 15 1/11,765 15 1/11,765 SD (1)
14 - < 1/200,000 - < 1/200,000 PD
15 - < 1/200,000 92 1/19,231 SD (18)
16 - < 1/200,000 - < 1/200,000 SD (2)
17 78 1/7,042 78 1/4,132 SD (16)
19 - < 1/200,000 20 1/20,833 SD (5)
20 - < 1/200,000 - < 1/200,000 PD
21 - < 1/200,000 - < 1/200,000 PD
22 9 1/12,821 9 1/12,821 PD
23 - < 1/200,000 - < 1/200,000 Surgical CR (13+)
24 - < 1/200,000 6 1/12,048 SD (3.5)
25 - < 1/200,000 3 1/18,868 PD
  1. The peak 5T4 specific responses detected at any time point to 5T4 peptides or 5T4 peptide plus protein. *; no detection of 5T4 responses. Positive responses are indicated as bold type.